News
Kamada gets contracts for AAT augmentation in Brazil
GlobesOnline
After obtaining marketing approval from Brazil’s National Health Surveillance Agency (Anvisa) for its intravenous alpha-1 antitrypsin (AAT) protein for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1), also known as genetic COPD, the Israeli biopharmaceutical company Kamada Ltd. announced that it has obtained export orders for AAT for the treatment of emphysema and cystic fibrosis for patients lacking the AAT protein, type D emphysema, and to vaccinate against fetal hemolytic disease, a fatal blood disease.
Kamada estimate in a press release that its sales in Brazil will total NIS 15 million ($4 million) in 2010.
